Digest Network Come funziona
Network
/
Società
Cl
Non verificato

ClearNote Health

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOncologiaSalute

11 comunicati stampa

Guarda tutti i comunicati
17/10/2025
Scienza
Oncologia
Tecnica
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Eventi
ClearNote Health to Showcase Latest Advancements in Early Cancer Detection Testing at ESMO Congress 2025
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
25/09/2025
Industria
Biotecnologia
Sanità
Attrezzature medico-sanitarie
Salute
Oncologia
ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
09/07/2025
Oncologia
Salute
Attrezzature medico-sanitarie
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
16/06/2025
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
23/04/2025
Eventi
Industria
Tecnica
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
ClearNote Health to Showcase Latest Advancements in Tumor Subtyping and Circulating Tumor Fraction Technologies at AACR Annual Meeting 2025
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
12/03/2025
Mercato del lavoro
Industria
Software
Sanità
Associazioni/Professionisti
Oncologia
Tecnica
Biotecnologia
Salute
ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
18/02/2025
Scienza
Biotecnologia
Attrezzature medico-sanitarie
Oncologia
Sanità
Salute
Industria
ClearNote Health Earns Approval for Avantect® Pancreatic Cancer Test from New York State Department of Health
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
07/01/2025
Analisi di mercato
Industria
Biotecnologia
Salute
Oncologia
ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
18/12/2024
Industria
Biotecnologia
Salute
Medicina - Varie
Oncologia
ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0
31/10/2024
Industria
Oncologia
Salute
Sanità
Biotecnologia
Avantect Pancreatic Cancer Test Cost-Effective When Used as a Surveillance Tool in High-Risk Patients Newly Diagnosed with Diabetes
Fonte
ClearNote Health
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0